YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas.

IF 2.3 4区医学 Q3 ONCOLOGY

Current cancer drug targets Pub Date : 2025-03-17 DOI:10.2174/0115680096328745250122231110

Miao Wang, Siyu Qian, Yue Zhang, Qingjiang Chen, Xudong Zhang, Mingzhi Zhang

{"title":"YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas.","authors":"Miao Wang, Siyu Qian, Yue Zhang, Qingjiang Chen, Xudong Zhang, Mingzhi Zhang","doi":"10.2174/0115680096328745250122231110","DOIUrl":null,"url":null,"abstract":"Introduction: Yippee Like 1 (YPEL1) is a nuclear protein involved in various cellular processes, including cell cycle regulation, senescence, and mammalian develop-ment. It plays a dual role in cancer, functioning as either an antitumor or tumor-promoting factor.Methods: In the current study, via The Cancer Genome Atlas (TCGA) search, we found that YPEL1 is aberrantly expressed in various cancers. High expression of YPEL1 corre-lated with poorer survival outcomes, whereas low expression of YPEL1 was associated with improved overall survival of patients. YT cell lines and gemcitabine-resistant YT cell line (YT/Gem-R) exhibit elevated levels of the YPEL1 protein.Result: Furthermore, we determined that knocking down YPEL1 in both YT cell and YT/Gem-R induces apoptosis and autophagy. Additionally, silencing YPEL1 significantly reduced the tumor growth the xenograft model.Conclusion: These findings suggest that YPEL1 exhibits the potential for being used as a target for NK / T cell lymphoma treatment.","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096328745250122231110","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Yippee Like 1 (YPEL1) is a nuclear protein involved in various cellular processes, including cell cycle regulation, senescence, and mammalian develop-ment. It plays a dual role in cancer, functioning as either an antitumor or tumor-promoting factor.

Methods: In the current study, via The Cancer Genome Atlas (TCGA) search, we found that YPEL1 is aberrantly expressed in various cancers. High expression of YPEL1 corre-lated with poorer survival outcomes, whereas low expression of YPEL1 was associated with improved overall survival of patients. YT cell lines and gemcitabine-resistant YT cell line (YT/Gem-R) exhibit elevated levels of the YPEL1 protein.

Result: Furthermore, we determined that knocking down YPEL1 in both YT cell and YT/Gem-R induces apoptosis and autophagy. Additionally, silencing YPEL1 significantly reduced the tumor growth the xenograft model.

Conclusion: These findings suggest that YPEL1 exhibits the potential for being used as a target for NK / T cell lymphoma treatment.

查看原文本刊更多论文

YPEL1抑制NK / T细胞淋巴瘤吉西他滨耐药的发展

Yippee Like 1 （YPEL1）是一种参与多种细胞过程的核蛋白，包括细胞周期调节、衰老和哺乳动物发育。它在癌症中起着双重作用，既可以作为抗肿瘤因子，也可以作为促肿瘤因子。方法：在本研究中，我们通过癌症基因组图谱（the Cancer Genome Atlas， TCGA）搜索，发现YPEL1在多种癌症中存在异常表达。高表达的YPEL1与较差的生存结果相关，而低表达的YPEL1与改善患者的总生存相关。YT细胞系和耐吉西他滨YT细胞系（YT/Gem-R）表现出YPEL1蛋白水平升高。结果：我们进一步发现，在YT细胞和YT/Gem-R中敲低YPEL1均可诱导细胞凋亡和自噬。此外，沉默YPEL1可显著降低异种移植瘤模型的肿瘤生长。结论：这些发现表明，YPEL1具有作为NK / T细胞淋巴瘤治疗靶点的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current cancer drug targets 医学-肿瘤学

CiteScore

5.40

自引率

0.00%

发文量

105

审稿时长

1 months

期刊介绍： Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes. Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer. As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.